Veracyte Inc
(FRA:12V)
€
39.4
0.8 (2.07%)
Market Cap: 3.16 Bil
Enterprise Value: 2.92 Bil
PE Ratio: 0
PB Ratio: 2.76
GF Score: 81/100 Veracyte Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 13, 2022 / 09:40PM GMT
Release Date Price:
€15.62
(-3.70%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst
Right. Thanks, everybody, for joining us. My name is Matt Sykes. I'm the life science tools and diagnostics analyst at Goldman Sachs. And today, we have the pleasure of hosting Veracyte, CEO, Marc Stapley; and Chief Financial Officer, Rebecca Chambers. Thank you. Marc and Rebecca, for being here today. Really appreciate it.
Marc A. Stapley
Veracyte, Inc. - CEO & Director
Thanks for having us.
Rebecca Chambers
Veracyte, Inc. - Executive VP & CFO
Thank you for having us.
Matthew Carlisle Sykes;Marc A. Stapley
Goldman Sachs Group, Inc., Research Division - Research Analyst
Maybe Marc, Rebecca, maybe will kind of set the -- help you set the stage for us, maybe some introductory comments about the year so far? And then maybe, Marc, this is probably about your 1-year anniversary, so maybe some highlights as you reflect back on your first year at Veracyte.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot